NCT07149740 · Optos, PLC
Data Gathering for A10900
What this study is about
The objective of this study is to gather Optical Coherence Tomography (OCT) data on normal and diseased eyes
View original scientific description
The objective of this study is to gather Optical Coherence Tomography (OCT) data on normal and diseased eyes
Interventions
DEVICE
OCT
A10900 is an optical coherence tomography device
Primary outcome measures
Number of OCT Scans
Time frame: 1 year
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Exclusion criteria
- Participants 22 years of age or older on the date of informed consent
- Participants able to understand the written informed consent and willing to participate as evidenced by signing the informed consent
- BCVA 20/400 or better in the study eye
- Participants presenting at the site with retinal disease
- Diagnosis of some type of retinal pathology by investigator, may include, but not limited to: Macular Degeneration (including participants with drusen and geographic atrophy and choroidal neovascularization), Diabetic Macular Edema, Diabetic Retinopathy, Macular Hole, Epiretinal Membrane, Central Serous Retinopathy and others Exclusion Criteria for Retinal Disease Group
- Participants unable to tolerate ophthalmic imaging
- Participants not able to obtain acceptable OCT images due to ocular media opacity or other reasons
- Participant has a condition or is in a situation which the investigator feels may put the participant at significant risk, may confound the study results, or may interfere significantly with the participant's participation in the study
- Presence of glaucoma or any ocular pathology other than a retinal pathology in the study eye as determined by self-report and/or investigator assessment at the study visit; Inclusion Criteria for Glaucoma Group
- Participants 22 years of age or older on the date of informed consent
- Participants able to understand the written informed consent and willing to participate as evidenced by signing the informed consent
- BCVA 20/40 or better in the study eye
- History of Visual field defects within the previous year from the study visit or measured the day of the study visit consistent with glaucomatous optic nerve damage with at least one of the following two findings:
- On pattern deviation (PD), there exists a cluster of 3 or more points in an expected location of the visual field depressed below the 5% level, at least 1 of which is depressed below the 1% level;
- Glaucoma hemi-field test "outside normal limits."
- Glaucomatous optic nerve damage as evidenced by any of the following optic disc or retinal nerve fiber layer structural abnormalities:
- Diffuse thinning, focal narrowing, or notching of the neuroretinal rim, especially at the inferior or superior poles with or without disc hemorrhage;
- Optic disc neural rim asymmetry of the two eyes consistent with loss of neural tissue Exclusion Criteria for Glaucoma Group
- Participants unable to tolerate ophthalmic imaging
- Participants not able to obtain acceptable OCT images due to ocular media opacity or other reasons
- Participant has a condition or is in a situation which the investigator feels may put the participant at significant risk, may confound the study results, or may interfere significantly with the participant's participation in the study
- No reliable visual field test result within the previous year from the study visit, defined as fixation losses \> 33% or false positives \> 33%, or false negatives \> 33% in the study eye
- Presence of any ocular pathology except glaucoma in the study eye Inclusion Criteria for Corneal Group 1\. Participants 22 years of age or older on the date of informed consent 2. Participants able to understand the written informed consent and willing to participate as evidenced by signing the informed consent 3. Participants presenting at the site with corneal disease, for example but not limited to, corneal disorders due to contact lens wear, post-refractive surgery, dry eye, keratoconus 4. Participant is able to comply with the study procedures. Exclusion Criteria for Corneal Group
- Participants unable to tolerate ophthalmic imaging
- Participant has a condition or is in a situation which the investigator feels may put the participant at significant risk, may confound the study results, or may interfere significantly with the participant's participation in the study
- Participant with ocular media not sufficiently clear to obtain acceptable OCT images. Inclusion Criteria for Normal Group
- Participants 22 years of age or older on the date of informed consent
- Participants able to understand the written informed consent and willing to participate as evidenced by signing the informed consent
- Participants presenting at the site with normal eyes (Cataracts, LASIK, PRK, and peripheral pathology that does not affect the posterior pole region, for example lattice and peripheral drusen, are allowed).
- BCVA 20/40 or better (each eye)
- Participant is able to comply with the study procedures Exclusion Criteria for Normal Group
- Participants unable to tolerate ophthalmic imaging
- Participant has a condition or is in a situation which the investigator feels may put the participant at significant risk, may confound the study results, or may interfere significantly with the participant's participation in the study
- Participant with ocular media not sufficiently clear to obtain acceptable OCT images
- History of leukemia, dementia or multiple sclerosis
Where
- Anaheim, California
- West Hartford, Connecticut
- Wellesley Hills, Massachusetts
- Germantown, Tennessee
Related conditions & keywords
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Feb 13, 2026 · Source of record for eligibility and locations